Oppenheimer Holdings, Inc. set a $15.00 price target on CymaBay Therapeutics Inc. (NASDAQ:CBAY) in a research report report published on Monday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other brokerages have also recently issued reports on CBAY. Zacks Investment Research raised CymaBay Therapeutics from a sell rating to a hold rating in a research report on Monday, September 18th. Cantor Fitzgerald started coverage on CymaBay Therapeutics in a research report on Tuesday, September 19th. They issued an overweight rating and a $16.00 target price on the stock. Leerink Swann started coverage on CymaBay Therapeutics in a research report on Wednesday, August 23rd. They issued an outperform rating and a $12.00 target price on the stock. Ifs Securities reissued a strong-buy rating on shares of CymaBay Therapeutics in a research report on Monday, July 17th. Finally, Piper Jaffray Companies set a $7.00 target price on CymaBay Therapeutics and gave the stock a buy rating in a research report on Monday, July 17th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $14.00.
CymaBay Therapeutics (CBAY) remained flat at $9.20 during midday trading on Monday. The company’s stock had a trading volume of 525,325 shares. CymaBay Therapeutics has a 12-month low of $1.15 and a 12-month high of $9.40. The stock’s 50 day moving average price is $8.00 and its 200 day moving average price is $6.05. The stock’s market cap is $402.56 million.
CymaBay Therapeutics (NASDAQ:CBAY) last announced its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.06). Equities research analysts expect that CymaBay Therapeutics will post ($0.82) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.com-unik.info/2017/10/31/cymabay-therapeutics-inc-cbay-given-a-15-00-price-target-at-oppenheimer-holdings-inc.html.
In other news, Director Kurt Von Emster sold 108,876 shares of the firm’s stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $7.85, for a total value of $854,676.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 15.10% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of CBAY. Bank of New York Mellon Corp raised its stake in CymaBay Therapeutics by 0.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 140 shares during the period. LVM Capital Management Ltd. MI raised its stake in CymaBay Therapeutics by 100.0% during the 2nd quarter. LVM Capital Management Ltd. MI now owns 20,000 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 10,000 shares during the period. Marshall Wace North America L.P. bought a new stake in CymaBay Therapeutics during the 2nd quarter valued at approximately $242,000. Ardsley Advisory Partners raised its stake in CymaBay Therapeutics by 66.2% during the 2nd quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock valued at $290,000 after purchasing an additional 20,000 shares during the period. Finally, Renaissance Technologies LLC raised its stake in CymaBay Therapeutics by 97.6% during the 1st quarter. Renaissance Technologies LLC now owns 231,949 shares of the biopharmaceutical company’s stock valued at $997,000 after purchasing an additional 114,549 shares during the period. 25.87% of the stock is currently owned by institutional investors.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
What are top analysts saying about CymaBay Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CymaBay Therapeutics Inc. and related companies.